Sanofi CEO: Vaccine candidate will not be ready in 2021 | TheHill – The Hill

Sanofi CEO Paul Hudson said that a COVID-19 vaccine prospect that the company is establishing will not be prepared in 2021. “This vaccine will not be prepared this year, but it could be of usage at a later stage even more if the battle against variations was to continue,” Reuters reported Hudson informed French paper Le Journal du Dimanche. The CEO gave no other information, according to the news outlet. The Hill has actually reached out to the company for comment.Sanofi partnered with U.S.-based business Translate Bio last June to developed the vaccine based upon mRNA technology. Vaccines from Pfizer/BioNTech and Moderna– which have actually both been authorized for emergency usage in the U.S.– also use this technology.Reuters reported that scientific trials of the companys vaccine were anticipated to start this quarter, and Sanofi stated in December that the “earliest possible approval” of the vaccine was the 2nd half of 2021. Sanofi revealed in December that interim results from a stage 1/2 clinical trial of a separate vaccine it is developing with U.K.-based GlaxoSmithKline (GSK) revealed the candidate produced a low immune reaction in older grownups. The company at the time stated that the low immune reaction might be due to an insufficient concentration of the antigen. The business plans to start a phase 2b trial of this vaccine this month, a move that will postpone its availability to sometime in the 2nd half of 2021. The news follows Sanofi revealed in late January that it will help Pfizer and BioNTech produce dosages of their vaccine from its centers in Frankfurt, Germany, starting this summertime..

Leave a Reply

Your email address will not be published. Required fields are marked *